X

Stock Insiders: Nova Eye is confident its new canoplasty device will become a hit

Nova Eye is confident its new canoplasty device will become a hit

share

Stock Insiders is a podcast series focussed on investing, hosted by TV presenter and news journalist Christina Morrissy. 

In this episode Christina chats to Tom Spurling, managing director at Nova Eye Medical (ASX:EYE).

Nova Eye Medical is a medical technology company that develops, manufactures and sells a portfolio of proprietary glaucoma treatment technologies. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications, and the Molteno3 glaucoma drainage device for cases of severe and complex glaucoma.

The company’s new iTrack Advance is aimed at a broader market as it improves a key glaucoma procedure.

To hear Christina and Tom discuss all this and more, tune in below!

On mobile? Click here to listen with Apple podcasts, here for Spotify.

Like to tune in through another app? Just search for Stock Insiders with Christina Morrissy and subscribe!

Categories: Health & Biotech

share

Related Posts